Illumina develops and manufactures life sciences tools and integrated systems for the large scale-analysis of genetic variation and function.

Under the agreement, the term of supply will extend from three years to five years, terminating in July 2016.

Sequenom and its subsidiaries purchase Illumina’s sequencing equipment and consumables for use in the cell-free detection of fetal chromosomal abnormalities in maternal blood.